An important milestone was the commencement of the pediatric study in May 2023, which will provide insights over the coming years into the extent to which the innovative EASEE® device can expand the treatment options for children and adolescents. The study is open to 12 to 17-year-olds who suffer from medication-resistant epilepsy. The study is currently underway at the following centers:
- UK Freiburg
- UK Heidelberg
- Epilepsie-Zentrum Kehl Kork
- Schön Klinik Vogtareuth
- UK Frankfurt
- Epilepsie-Zentrum Bethel, Bielefeld
- Kepler UK Linz (AU)
At the same time, the Precisis team is working diligently to introduce EASEE® into additional European markets. Based on the positive feedback from the NHS in October 2023, EASEE® is expected to be available for epilepsy treatment in the United Kingdom from Q2 2024.
Since the EASEE® System is built on a platform technology, the device can potentially be adapted for use in other medical conditions in parallel to epilepsy. In the summer of 2023, the Precisis team decided to explore depression as another application area. Collaborations with various clinics are currently underway to plan potential scientific study protocols and project timelines. We anticipate receiving approval for a clinical study in the spring of 2024 to evaluate the therapeutic potential of EASEE® in the treatment of patients with severe medication-resistant depression.